Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Economic information and modeling reportBudget impact model

Cost assumptions

9 evidence topics · 10 sources

Budget impact model of ficerafusp alfa: cost assumptions

No evidence found.

Ficerafusp alfa price

No evidence found.

United States unit drug, administration, and terminal care costs used in a first-line cost-effectiveness model